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Abstract
Objective
Blood donors in Brazil have been routinely screened for HTLV-I/II since 1993. A
study was performed to estimate the prevalence of HTLV-I/II infection in a low risk
population and to better understand determinants associated with seropositivity.
Methods
HTLV-I/II seropositive (n=135), indeterminate (n=167) and seronegative blood donors
(n=116) were enrolled in an open prevalence prospective cohort study. A cross-
sectional epidemiological study of positive, indeterminate and seronegative HTLV-I/II
subjects was conducted to assess behavioral and environmental risk factors for
seropositivity. HTLV-I/II serological status was confirmed using enzyme-linked
immunosorbent assay (EIA) and Western blot (WB).
Results
The three groups were not homogeneous. HTLV-I/II seropositivity was associated to
past blood transfusion and years of schooling, a marker of socioeconomic status, and
use of non-intravenous illegal drugs.
Conclusions
The study results reinforce the importance of continuous monitoring and improvement
of blood donor selection process.
Resumo
Objetivo
Doadores de sangue no Brasil têm sido avaliados sorologicamente para o HTLV-I/
II desde 1993. Assim, realizou-se estudo para estimar a prevalência dessa infecção
em população de baixo risco e para melhor compreender os determinantes associados
à soropositividade.
Métodos
Doadores de sangue soropositivos (n=135), soroindeterminados (n=167) e
soronegativos (n=116) foram arrolados como participantes de uma coorte aberta e
prevalente. Estudo transversal dos participantes desses três grupos avaliou fatores
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INTRODUCTION
Human lymphotropic viruses types I and II (HTLV
I/II) were the first reported human retroviruses, hav-
ing been isolated in the beginning of the 80s (Poiez
et al 13). In regions considered endemic (Caribbean,
Africa and Southwest Japan), HTLV-I antibody preva-
lence range from 3% to 15%, it is higher in older
individuals and in females (Blattner et al;1 Chavance
et al;3 Tokudome et al15). Although it shares 65% of
its genome with type I, HTLV-II is much less preva-
lent, predominating in native populations of the
American continent and among injecting drug users
in the United States and Europe (Hall et al5). The vi-
rus is transmitted vertically, especially through
breastfeeding (Hirata et al6), sexually (Kajiyama et
al8), and with the exposure to infected blood, mostly
through blood transfusions or syringes and needles
sharing among intravenous drug users (Sullivan et
al,14 Okochi et al12).
HTLV-I/II serological screening has become man-
datory in Brazilian blood banks since November
1993. Among the 405,437 volunteers donating blood
at Hemominas Blood Center, between January 1994
to January 1999, 3,203 (0.79%) were EIA positive.
For those 405,437 blood donors, 244 (0.06%) were
confirmed as positive in the Western Blot test and
1,454 (0.36%) were considered indeterminate.
An open prevalence prospective cohort study (The
Interdisciplinary HTLV-I/II Research Group [GIPH]
Cohort Study) is being conducted at the Hemominas
Blood Center since March 1997. In an attempt to
better understand the epidemiological aspects of the
virus seroprevalence, and to define the infections
determinants in this population, as well as to subsi-
dize the screening criteria in local blood banks, a-
case-control study with cross-sectional features of the
social-economic, demographic and behavior vari-
ables at baseline of the GIPH Cohort Study partici-
pants was conducted.
de risco comportamentais e ambientais para soropositividade. O status sorológico
foi definido usando a reação de EIA (enzyme linked immunosorbent assay) e o teste
Western blot (WB).
Resultados
Os três grupos apresentaram heterogeneidade entre si. A soropositividade mostrou-
se associada à história pregressa de transfusão de sangue, em nível educacional,
como um marcador de condição socioeconômica e ao uso de drogas ilegais não
endovenosas.
Conclusões
Os resultados confirmam a importância de um monitoramento e refinamento do
processo de seleção dos doadores de sangue.
METHODS
Hemominas Institute is located in the metropoli-
tan area of Belo Horizonte , state of Minas Gerais,
Southeast Brazil. Belo Horizonte has about
4,000,000 inhabitants and it is the third largest city
in Brazil. Hemominas Institute, the blood bank of
the state of Minas Gerais, is the largest blood bank
in the city. In 2000 an average of 7,000 individuals/
month donated blood at Hemominas and 15,000
blood transfusions/month were made. After a rou-
tine pre-donation screening questionnaire and clini-
cal examination, individuals who are considered
eligible for blood donation - aged between 18 and
60 years, good general health, not being exposed to
retrovirus risk factors (for example, use of illegal
injecting drugs, unsafe sexual behavior, tattoos), and
not having received blood or blood products trans-
fusions in the last 10 years - are tested for blood
transmitted infections, namely HIV-1/2, HBV, HCV,
T. cruzi, T. pallidum and HTLV-I/II. Blood donors in
Brazil are all volunteers because any reimbursement
for blood donation is prohibited by law.
For HTLV-I/II, an eligible donor is considered posi-
tive when their enzymatic serological testing
(ELISA) is reactive, and the confirmatory testing,
Western Blot (WB), also shows positive results ac-
cording to the manufacturers instructions: there is a
band at p24 and gp46 or p21env (1998); reactivity
to GAG (p19 and p24) and ENV (GD21) - (1998 to
2000). A reactive EIA and the presence of any band
pattern different from manufacturers criteria for
positivity is classified as indeterminate. Individu-
als whose EIA test was not reactive are considered
seronegative; also, those whose EIA test was not
reactive and there were no bands in the Western Blot
are considered seronegative.
Any former blood donor of the Hemominas Institute
living in the metropolitan area of Belo Horizonte with
HTLV-I/II positive or indeterminate results since the
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start of the GIPH Cohort Study were eligible to the
study. A sample of seronegative donors (n=348)
selected using a systematic random sampling, who
donated blood during the same period of time in the
same network, was included in the study. Subjects
with abnormal serology, as well as the seronegative
group, were contacted by mail and invited to an initial
interview. After informed and counseled about their
serological status, the study objective and proce-
dures, an informed consent was obtained from those
willing to participate. Data collected during the
baseline visit of study participants were analyzed
and results are presented here.
All subjects answered the same questionnaire to
the same interviewer in a private environment. The
interviewer, who is one of the authors (BCS), was
aware of participants serological results. The inter-
views were conducted from March 1997 to June 1999.
The questionnaire was designed to elicit data on
(a) demographics such as education level, personal
monthly income, and occupation; (b) HTLV-I/II trans-
mission: breastfeeding, blood transfusion at any time
in the past, intravenous injection of illegal drugs,
syringe and needle sharing, accidents involving an-
other persons blood, tattoos, and acupuncture treat-
ment. Questions about use of any recreational illegal
drug and; (c) sexual history: number of partners, paid
sex and male homosexual contacts were also asked.
For women, information about reproductive history
was also obtained.
To guide the interpretation, crude and stratified
prevalence rates were calculated along with preva-
lence odds ratio and 95% confidence interval. Since
all the variables were categorical, the answers were
compared within the groups (positive, indetermi-
nate and negative) using cross tabulation. The dif-
ferences were tested for significance using the X²
test or, when indicated, Fishers exact test.
Multinomial logistical regression models were also
fitted to the data to better compare the three groups
simultaneously (Hosmer & Lemeshow7). The vari-
ables shown to be statistically significant in the
bivariate analysis were added to the logistical
model (forward selection), and maintained in the
final model if p<0.05 or if presenting biological
plausibility to justify their remaining in the model,
despite the p-value. Data analysis was conducted
using Stata 6.0.
The Hemominas Institutional Board approved the
study procedures.
RESULTS
During the study period, of all seropositive sub-
jects (n=180) invited to participate in the GIPH Co-
hort Study, 75.0% (n=135) signed a consent as com-
pared to about 33.0% of the indeterminate (n=506)
and negative (n=348) groups. No significant differ-
ence in behavior and demographic variables distri-
bution was found when comparing responding and
non-responding subjects as a group or according to
serologic results (data not shown).
The average subject age was 33 years, and 66.8%
Table 1 - Frequency distribution of HTLV-I/II serostatus according to demographic and behavior characteristics at baseline.
The GIPH Cohort Study. Belo Horizonte, Brazil, 1997-1999.
Variables HTLV-I/II positive (N=135) HTLV-I/II indeterminate (N=167) HTLV-I/II negative (N=116)
N (%) N (%) N (%)
Men Women Men Women Men Women
74 (100.0) 61 (100.0) 126 (100.00) 41 (100.0) 75 (100.0) 41 (100.0)
Age (years)
18-29 23 (31.1) 16 (26.2) 58 (46.0) 17 (41.5) 44 (58.7) 21 (51.2)
30-39 25 (33.8) 18 (29.5) 46 (36.5) 9 (22.0) 20 (26.7) 13 (31.7)
40-49 20 (27.0) 17 (27.8) 18 (14.3) 10 (24.4) 8 (10.6) 5 (12.2)
50-60 6 (8.1) 10 (16.5) 4 (3.2) 5 (12.1) 3 ( 4.0) 2 (4.9)
Formal education
≥8 years 12 (16.2) 16 (28.1) 42 (33.3) 18 (43.9) 38 (50.7) 26 (63.4)
<8 years 62 (83.8) 41 (71.9) 84 (66.7) 23 (56.1) 37 (49.3) 15 (36.6)
NA* 4
Blood transfusion
No 60 (83.3) 45 (86.5) 115 (93.5) 34 (89.5) 74(100.0) 39 (95.1)
Yes 12 (16.7) 7 (13.5) 8 (6.5) 4 (10.5) 0 (0. 0) 2 (4.9)
NA* 2 9 3 3 1
Breastfed
No 2 (2.7) 2 (3.6) 1 (0.8) 1 (2.7) 2 (2.9) 5 (12.5)
Yes 72 (97.3) 54 (96.4) 115 (99.2) 36 (87.3) 68 (97.1) 35 (87.5)
NA* 5 10 4 5 1
Non-intravenous
Illegal drugs
No 65 (87.8) 50 (87.8) 110(87.3) 32 (80.0) 71 (94.7) 39 (97.5)
Yes 9 (12.2) 7 (12.2) 16 (12.7) 8 (20.0) 4 (5.3) 1 (2.5)
NA* 4 1 1
*NA: Information not available.
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Table 2 - Bivariate analysis for HTLV-I/II serologic status according to selected determinants at baseline: seropositive versus
seronegative groups. The GIPH Cohort Study. Belo Horizonte, Brazil, 1997-1999.
Variables HTLV-I/II positive HTLV-I/II negative OR 95% CI*
N=135 N=116
N (%) N (%)
Sex
Male 78 (57.8) 75 (64.7) 1.00
Female 57 (42.2) 41 (35.3) 1.34 (0.78-2.30)
Age (years)
18 to 29 39 (28.9) 65 (56.0) 1.00
30 to 39 43 (31.9) 33 (28.5) 2.17 (1.14-4.16)
40 to 49 37 (27.3) 13 (11.2) 4.74 (2.12-10.75)
50 to 59 16 (11.9) 5 (4.3) 5.33 (1.66-18.23)
Formal education
≥8 years 28 (20.7) 64 (55.2) 1.00
<8 years 107 (79.3) 52 (44.8) 4.70 (2.61-8.52)
Breastfed
No 4 (3.0) 7 (6.4) 1.00
Yes 126 (97.0) 102 (93.6) 2.16 (0.53-10.32)
NA 5 7
Non-intravenous
Illegal drugs
No 117 (86.7) 110 (95.7) 1.00
Yes 18 (13.3) 5 (4.3) 3.38 (1.15-10.82)
NA 1
Blood transfusion
No 105 (84.7) 113 (98.3) 1.00
Yes 19 (15.3) 2 (1.7) 10.22 (2.22-65.16)
NA 11 1
Paid sex**
No 40 (53.3) 48 (71.6) 1.00
Yes 35 (46.7) 19 (28.4) 1.43 (1.04-4.73)
NA 3 8
*Odds ratio and 95% Confidence Interval.
**For males only.
were males. HTLV-I/II prevalence was higher in women
(41.0%) than men (28.0%) (Table 1).
In the bivariate analysis (Table 2), when compared
to seronegative donors, HTLV-I/II seropositive sub-
jects were more often older, had fewer years of school-
ing, used non-intravenous recreational illegal drugs
(marijuana as almost the single drug used), had blood
transfusions in the past and paid for sex (males only).
The indeterminate subjects when compared to seron-
egative donors (Table 3) were more likely to have
fewer years of schooling, breastfeeding, use of non-
intravenous recreational illegal drugs, blood transfu-
sions in the past and paid sex (males only). No sig-
nificant difference between the groups was found for
the frequency distribution of tattoos, acupuncture and
intravenous drugs use (data no shown).
The multinomial logistical regression model was
applied to the group as a whole (Table 4). The final
model comparing positive and indeterminate subjects
to the negative group identified three main variables
after adjusting for age and sex: history of previous
transfusions, less than eight years of schooling, and
use of non-intravenous recreational illegal drugs in
the past. In Brazil schooling years is a well-recog-
nized and accurate surrogate of socio-economic sta-
tus. As education and monthly income are strongly
correlated, only the variable education was included
in the study models. For this study, education was
assumed to be a measurement with higher accuracy
and reliability than income.
DISCUSSION
The study results revealed remarkable lack of ho-
mogeneity between the three studied groups. This is
very important when considering that all study sub-
jects had self-assessed themselves as healthy enough
to volunteer for blood donation. Also, all subjects
were clinically asymptomatic when submitted to the
routine pre-donation screening questionnaire and
clinical examination conducted at Hemominas Insti-
tute. For the seropositive group it was observed an
growing trend in the OR with increasing in the study
population age (Table 4). The greater 95% confidence
intervals may have resulted from small numbers es-
pecially for the 50-59 age group. Several different
hypothesis can be formulated: the higher antibody
titers in subjects infected for longer periods of time,
the continuous addition of new infected individuals
and the cohort effect, with older groups reflecting the
highest infection prevalence rate in the past
(Yamaguchi,16 Murphy et al11).
From 1994 to 1998, women represented 22.9%
(93,940/405,437) of the Hemominas Institute donors,
and 42.2% (57/135) of the HTLV-I/II seropositive sub-
jects. The higher seroprevalence in women than men
points out to a higher effectiveness in transmission
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Table 3 - Bivariate analysis for HTLV-I/II serologic status according to selected determinants at baseline: indeterminate group
versus negative group. The GIPH Cohort Study. Belo Horizonte, Brazil, 1997-1999.
Variables HTLV-I/II indeterminate HTLV-I/II negative OR 95% CI*
N=166 N=116
N (%) N (%)
Sex
Male 126 (75.9) 75 (64.7) 1.00
Female 40 (24.1)  41 (35.3) 0.57 (0.33-0.98)
Age (years)
18 to 29 74 (44.6) 65 (56.0) 1.00
30 to 39 55 (33.1) 33 (28.5) 1.44 (0.81-2.58)
40 to 49 28 (16.8) 13 (11.2) 1.87 (0.84-4.17)
50 to 59 9 (5.4) 5 (4.3) 1.56 (0.45-5.68)
Formal education
≥8 years 60 (36.1) 64 (55.2) 1.00
<8 years 106 (63.9) 52 (44.8) 2.19 (1.32-3.67)
Breastfed
No 2 (1.3) 7 (6.4) 1.00
Yes 152 (98.7) 102 (93.6) 5.22 (0.97-37.1)
NA 12 7
Non-intravenous
Illegal drugs
No 143 (86.1) 110 (95.7) 1.00
Yes 23 (13.9) 5 (4.3) 3.54 (1.22-10.99)
NA 1
Blood transfusion
No 149 (92.5) 113 (98.3) 1.00
Yes 12 (7.5) 2 (1.7) 4.55 (0.94-30,06)
NA 5 1
Paid sex**
No 58 (48.3) 48 (71.6) 1.00
Yes 62 (51.7) 19 (28.4) 2.70 (1.36-5.40)
NA 6 8
*Odds ratio and 95% Confidence Interval.
**For males only.
Table 4 - Multinomial logistic regression of HTLV-I/II serological status according to selected variables, at baseline. GIPH
Cohort Study. Belo Horizonte, 1997-1999.
Variables HTLV-I/II positive* HTLV-I/II indeterminate* 95% CI
Sex
Male 1.00** 1.00**
Female 0.72 0.40-1.28 1.64 0.95-2.84
Age
18-29 1.00 1.00
30-39 1.61 0.83-3.11 1.24 0.70-2.22
40-49 3.76 1.69-8.34 1.74 0.81-3.73
50-59 2.53 0.78-8.14 1.17 0.36-3.84
Transfusion
No 1.00 1.00
Yes 10.02 2.17-46.33 4.84 1.04-22.96
Formal education
>8 years 1.00 1.00
≤8 years 4.06 2.21-7.45 1.97 1.78-3.29
Non-intravenous
Illegal drugs
No 1.00 1.00
Yes 3.25 1.08-9.73 3.57 1.28-9.92
*HTLV-I/II negative is the comparison group.
**Odds ratio and 95% Confidence Interval.
from men to women, and/or to hormonal factors and
possibly other unknown determinants and exposures.
All these findings corroborate previous reports (Manns
& Blattner,10 Clark4) where the interplay of two or more
determinants was suggested (Kajiyama et al,8 Clark et
al,4 Brodine et al2). However, in the final logistic re-
gression model, after adjusting for age, previous his-
tory of transfusion, years of schooling and use of ille-
gal non-intravenous drugs, it was found that HTLV-I/II
serological status was independent of participants sex.
It is possible that in the study population, sex may be
a marker of social inequality and/or a confounder of
the association of HTLV-I/II serology and education - a
marker for socio-economic status.
The results of the indeterminate group should be
considered bearing in mind that this group has sub-
jects with false positive results (cross-reaction? ma-
laria? dengue? other retroviruses?) who could be
infected with different virus strains (Chavance et
al,3 Kaplan et al9) as well as the individuals actu-
ally infected with HTLV-I/II without a full-blown
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serological response detectable in the Western blot.
The present results clearly show that the indetermi-
nate group is different from the seropositive and se-
ronegative groups, presenting demographics and
behavior characteristics (e. g., sex, age, breastfeeding)
similar to the negative group, but matching the posi-
tive group in terms of past history of blood transfu-
sions, less than eight years of schooling and use of
recreational non-intravenous drugs (Tables 2, 3 and
4). Eleven percent of the indeterminate subjects had
positive polymerase chain reaction (PCR). Of these,
some have shown overt seroconversion at the time of
the biannual reevaluation (manuscript in preparation).
To ones knowledge, not much has been investigated
about the epidemiological characteristics of the in-
determinate group, which makes it difficult to com-
pare the study data with the literature.
The present study has allowed the evaluation of
various demographics, socio-economic and
behavior characteristics associated to HTLV-I/II in-
fection, and contrasts between positive and indeter-
minate serology groups. Some new determinants
associated with HTLV-I/II seropositivity were iden-
tified, such as non-intravenous use of recreational
illegal drug use, especially marijuana, and low socio-
economic conditions, measured by years of school-
ing, both of them relatively valid markers for in-
come and social status. These data point out toward
significant inequalities as determinants of exposure
to HTLV-I/II infection. The study population, where
well-known determinants of HTLV-I/II infection were
by definition exclusion criteria of study participa-
tion, make possible to show inequalities of the study
population as a determinant of HTLV-I/II
seroprevalence. Although lower education has been
associated with higher risk of other blood-borne
virus infections, such as HIV and Hepatitis B and C
(Goubau*), it has not been conclusively associated
with HTLV infection.
Some study limitations should be also considered.
For example, blood donors are not representative of
the base population in age and sex distribution and
may be also healthier, a possible healthy blood do-
nor effect. Concerning HTLV-I/II distribution in the
base population, seropositive blood donors are more
likely to include younger asymptomatic males in-
dividuals who were more recently infected. Al-
though most of HTLV-I/II seropositive individuals
are apparently asymptomatic through out their lives,
the study cross-sectional data analysis may have
resulted in an undetected survival bias. Also, as for
all individuals donating blood in a public health
blood center, participants were informed of their
serologic results before being invited to join the
study. As a consequence, neither participants nor
the interviewer were blind as for participants sero-
logical status. Although only one experienced and
well-trained interviewer conducted all interviews,
interviewer bias may not be ruled out. The advan-
tages of this population are that blood donors sta-
tus is more easily and less expensively ascertained
as compared to a random sample of the base popula-
tion, and these individuals are also a healthier non-
institutionalized population.
The strong association between blood transfusions
in the past year and uncertainties concerning chronic
infection, as well as the actual significance of inde-
terminate results call for a careful approach regard-
ing counseling and follow-up protocols.
In this manner, it will be possible to elaborate pub-
lic health measures to minimize the risk of asympto-
matic HTLV infected individuals developing HTLV-
I/II-related diseases, and to control virus transmis-
sion. It is believed that the studys findings may be
valuable in the reevaluation of criteria for blood do-
nor selection, further understanding of virus infec-
tion spread and prevention, and reinforcing the need
of a more in depth assessment of the indeterminate
serology group.
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